Pharmalittle: We're Reading About Novo Nordisk Boosting Consumer Focus, FDA Approving a Gene Therapy, and More

Pharmalittle: We're reading about Novo Nordisk boosting consumer focus, FDA approving a gene therapy, and more

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is still shaping up, although we do plan to attack our to-do list of chores and errands, promenade with the official mascots, and escort Mrs. Pharmalot to a soiree. We also hope to hold yet another listening party, where the rotation will likely include this, this, this, thi…

Mars CEO joins board of Ozempic-maker Novo Nordisk

Novo Nordisk has appointed Poul Weihrauch, CEO of US food giant Mars, as board observer as the Danish drugmaker seeks to strengthen its position in the highly competitive US obesity market.

Novo Nordisk adds Mars CEO as board observer (NVO:NYSE)

Novo Nordisk (NVO) stock is in focus as the company names Mars CEO Poul Weihrauch as board observer and adds three new directors. Read more here.

Novo chair re-elected despite dual role criticism - The Copenhagen Post

Lars Rebien Sørensen has been re-elected as Chairman of the Board at Novo Nordisk for a one-year term. During the annual general meeting, three new members were elected, including Genmab CEO Jan van de Winkel, while Mars CEO Poul Weihrauch joined as an observer to provide a consumer-oriented focus. Sørensen faced criticism for his dual […]